Broadcast Date: 
  • Time: 

The possibilities for gene therapies are being realized as candidates come to market with hundreds more in development. Adeno-associated virus (AAV) is a common vector, yet current production, purification, and analytics are far from optimal. Here we focus on the keys to a successful process—high viral genome productivity and % full capsids in the harvested material, with high overall yield and efficient impurity removal.

Join us for this GEN webinar, to hear the latest on the scalable start-to-finish rAAV process that has been refined for over two years. Our expert speaker, Dr. Åsa Hagner McWhirter, will cover a vast array of topics from production using single-use bioreactors to harvesting, filtration, and purification. Additionally, Dr. McWhirter will describe how to maximize full capsids with anion exchange polishing, using a single resin and protocol for AAV2, AAV5, AAV8, and AAV9 serotypes—as well as provide data from improved analytics with SPR assays.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.


Webinar produced with support from:

cytiva logo


Asa Hagner McWhirter headshot
Åsa Hagner McWhirter, PhD
Principal Scientist